Interim – Page 3 – Communicable Diseases Research

Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines

Review

Published on 2021-09-062022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] Nicotiana benthamaiana affected approach candidate Candidates clinical trial clinical trials convalescent coronavirus coronavirus disease COVID-19 COVID-19 vaccine COVID-19 vaccine development CoVLP CoVLP vaccine current demonstrated development diagnosing Ebola effective Effective vaccines Efficacy effort encapsulate Gaucher Disease glycoengineering immunization infectious disease outbreak Interim monoclonal antibody Neutralizing antibody response outbreak pandemic plant-based vaccine plants plasma preclinical study Prevalence RBD Safe SARS-CoV-2 SARS-CoV-2 variant Spike protein Spread status Strategy Subunit vaccine the vaccine transmission rate VLP ZMapp
[DOI] 10.3390/vaccines9090992 PMC 바로가기 [Article Type] Review

Improving Social Justice in COVID-19 Health Research: Interim Guidelines for Reporting Health Equity in Observational Studies

Article

Published on 2021-09-042022-10-29
Journal: International Journal of Environmental Research an [Category] COVID-19, SARS,

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

중등도 코로나바이러스 질환 2019(COVID-19) 환자 치료를 위한 AVIFAVIR: 2상/3상 다기관 무작위 임상 시험의 중간 결과

Clinical Trial

Published on 2021-08-022022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제,

[키워드] AVIFAVIR clearance clinical clinical trial COVID-19 COVID-19 patients Favipiravir Interim Ministry of Health Patient phase Registration Result RNA polymerase inhibitor Safe SARS-CoV-2 SARS-CoV-2 viral Treatment treatment of COVID-19 patients viral clearance
[DOI] 10.1093/cid/ciaa1176 PMC 바로가기 [Article Type] Clinical Trial

Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province

Article

Published on 2021-06-102022-10-28
Journal: Vaccines [Category] COVID-19,

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021

Full Report

Published on 2021-05-212022-10-30
Journal: Morbidity and Mortality Weekly Report [Category] COVID-19,

[키워드] COVID-19 estimate Interim Moderna Pfizer-BioNTech
[DOI] 10.15585/mmwr.mm7020e2 PMC 바로가기 [Article Type] Full Report

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

12~15세 청소년의 화이자-바이오엔텍 코로나19 백신 사용에 대한 예방접종 관행 자문위원회의 임시 권고 — 미국, 2021년 5월

Full Report

Published on 2021-05-212022-09-10
Journal: Morbidity and Mortality Weekly Report [Category] 신약개발,

[키워드] Adolescent Committee COVID-19 Interim Pfizer-BioNTech United States Year
[DOI] 10.15585/mmwr.mm7020e1 PMC 바로가기 [Article Type] Full Report

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Ad26.COV2.S 코비드-19 백신의 1-2a상 시험 중간 결과

Clinical Trial

Published on 2021-05-132022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus administration adverse event age All participants Antibody Response assigned authority candidate vaccine CD4+ T-cell CD8+ T-cell Cohort cohorts collected coronavirus coronavirus disease Coronavirus disease 2019 COV1001 COV2.S Department development dose Factor fatigue Fever full-length geometric mean geometric mean titer GMT headache healthy High dose Human increase in Infection Injection-site pain Interim Johnson & Johnson less low dose milliliter multicenter myalgia Neutralizing-antibody Neutralizing-antibody titers Older pandemic participant phase Placebo placebo-controlled primary end point profile provided Randomly reached reactogenicity receive regimen remained reported research and development respiratory response responses Result robust SARS-CoV-2 SARS-CoV-2 spike protein second dose serotype severe acute respiratory syndrome Coronavirus Spike protein Support systemic systemic adverse events T cells T-cell responses titer titers Trial two-dose regimen type 1 helper Vaccine vaccine candidate vaccine dose Viral viral particle wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Observational Study

Published on 2021-05-012022-10-04
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 95% CI age Analysis association BNT162b2 mRNA BNT162b2 mRNA vaccine ChAdOx1 nCoV-19 ChAdOx1 vaccine challenge clinical trial COVID-19 COVID-19 vaccination COVID-19 vaccine Cox model defined disease Effect Effectiveness Efficacy enhanced finding first dose funding Hospital admission individual Industrial Innovation Interim mass Medical Research Council National Older Patient Pfizer–BioNTech Phase 3 Poisson regression model positive primary care prospective cohort study reduced Registered residual confounding Result reverse transcription-PCR risk shown Strategy study period substantial reduction tested vaccination Vaccine were excluded
[DOI] 10.1016/S0140-6736(21)00677-2 PMC 바로가기 [Article Type] Observational Study

Interim estimates in null models of COVID-19 vaccine effectiveness

COVID-19 백신 효과의 null 모델에 대한 중간 추정치

Article

Published on 2021-05-012022-09-11
Journal: International Journal of Infectious Diseases [Category] SARS, 임상,

Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study

Article

Published on 2021-04-222022-10-31
Journal: International journal for equity in health [Category] COVID-19,